Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
adrenal tumor
androgens
hypogonadism
mitotane
testosterone
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
12
2022
accepted:
22
03
2023
medline:
21
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied. This single-center retrospective longitudinal study was undertaken to assess the frequency of testosterone deficiency before and after mitotane therapy, the possible mechanism involved, and the relationship between hypogonadism with serum mitotane levels and prognosis. Consecutive male ACC patients followed at the Medical Oncology of Spedali Civili Hospital in Brescia underwent hormonal assessment to detect testosterone deficiency at baseline and during mitotane therapy. A total of 24 patients entered the study. Of these patients, 10 (41.7%) already had testosterone deficiency at baseline. During follow-up, total testosterone (TT) showed a biphasic evolution over time with an increase in the first 6 months followed by a subsequent progressive decrease until 36 months. Sex hormone binding globulin (SHBG) progressively increased, and calculated free testosterone (cFT) progressively decreased. Based on cFT evaluation, the proportion of hypogonadic patients progressively increased with a cumulative prevalence of 87.5% over the study course. A negative correlation was observed between serum mitotane levels >14 mg/L and TT and cFT. Testosterone deficiency is common in men with ACC prior to mitotane treatment. In addition, this therapy exposes these patients to further elevated risk of hypogonadism that should be promptly detected and counteracted, since it might have a negative impact on quality of life.
Identifiants
pubmed: 37077359
doi: 10.3389/fendo.2023.1128061
pmc: PMC10108714
doi:
Substances chimiques
Mitotane
78E4J5IB5J
Androgens
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1128061Informations de copyright
Copyright © 2023 Delbarba, Cosentini, Facondo, Laganà, Pezzaioli, Cremaschi, Alberti, Grisanti, Cappelli, Ferlin and Berruti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Endocrinol Metab. 2011 Jun;96(6):1844-51
pubmed: 21470991
N Engl J Med. 2007 Jun 7;356(23):2372-80
pubmed: 17554118
J Clin Med. 2019 Nov 02;8(11):
pubmed: 31684071
Cancers (Basel). 2022 Nov 29;14(23):
pubmed: 36497381
Endocr Connect. 2020 Oct;9(10):1009-1018
pubmed: 33064664
Expert Opin Pharmacother. 2022 Aug;23(12):1413-1424
pubmed: 35876101
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937772
J Endocrinol Invest. 2014 Mar;37(3):207-17
pubmed: 24458831
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
J Clin Endocrinol Metab. 2005 Jan;90(1):157-62
pubmed: 15509641
J Endocrinol. 2013 Jul 29;218(3):275-85
pubmed: 23814013
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638485
J Clin Endocrinol Metab. 2017 Apr 01;102(4):1358-1365
pubmed: 28324035
Endocrine. 2022 Sep;77(3):438-443
pubmed: 35567656
Endocr Relat Cancer. 2008 Dec;15(4):1043-53
pubmed: 18824557
Pediatr Clin North Am. 1987 Aug;34(4):1055-66
pubmed: 3302892
Clin Endocrinol (Oxf). 2021 Feb;94(2):141-149
pubmed: 32996176
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Cancers (Basel). 2020 Apr 10;12(4):
pubmed: 32290298
Andrology. 2020 Sep;8(5):970-987
pubmed: 32026626
Infection. 2021 Apr;49(2):295-303
pubmed: 33289905
Eur J Endocrinol. 2013 Jul 29;169(3):263-70
pubmed: 23704714
J Endocrinol Invest. 2022 Dec;45(12):2385-2403
pubmed: 36018454
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107